1. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
    Xuan Zhao et al, 2022, Frontiers in Immunology CrossRef
  2. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
    null Kloten et al, 2019, Cells CrossRef
  3. Prospects of epigenetic therapy of head and neck squamous cell carcinoma
    R. N. Mustafin, 2023, Head and Neck Tumors (HNT) CrossRef
  4. Options for the development of colorectal cancer immunotherapy
    Rustam N. Mustafin, 2023, Kazan medical journal CrossRef
  5. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
    Kristina Buder-Bakhaya et al, 2018, Frontiers in Immunology CrossRef
  6. The Method of Viral Mimicry in Oncology and Prospects for its Improvement
    R. N. Mustafin, 2023, The Russian Archives of Internal Medicine CrossRef

  7. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer


    Yuxin Cheng et al, 2020, Cancer Management and Research CrossRef
  8. Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
    Julien Ancel et al, 2023, Frontiers in Immunology CrossRef
  9. Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy
    Takahiro Okabe et al, 2020, Cancers CrossRef